UTHR (United Therapeutics Inc.) Multiplikator Forward P/S

Lambang korporat lan logo United Therapeutics (UTHR)

United Therapeutics maintains its leadership in pulmonary hypertension therapy through the development of drug delivery systems and xenotransplantation. The forward P/S ratio highlights periods where investors revalue expected revenues, with the metric currently hovering around 7.60. The company's monopoly status is reinforced by the creation of a patient life-support ecosystem, while its environmental strategy is based on the construction of carbon-neutral LEED laboratories.

United Therapeutics Corporation - Multiplikator Forward P/S UTHR (periode 04.07.2022 - 16.11.2026)

Ringkesan rincian data analitis United Therapeutics (UTHR)

Analisis fundamental perusahaan:United Therapeutics Corp (UTHR)
Produk asli United Therapeutics Inc.

United Therapeutics (UTHR) maintains a monopoly position within the orphan disease niche, ensuring significant pricing power and a stable cash flow. The company's forward P/S ratio compares current market capitalization with expected revenue for the coming year, allowing for an assessment of the premium paid for future sales. Analyzing this chart helps investors recognize an overvalued asset in a timely manner and avoid buying at local peaks.

Pesaing United Therapeutics

Rasio rega marang prakiraan pendapatan Vertex VRTX|ALNY (Alnylam Inc.) - Rega mangsa ngarep marang pendapatan|Insmed Incorporated - Multiplikator Forward P/S|Rega forward marang dodolan BMRN (BioMarin Pharmaceutical)|BBIO: Multiplikator Forward P/S|BGM Group Corp - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Cogent Bio|XERS: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan kerostx.com (KROS)|Multiplikator forward rega marang pendapatan Arcturus Therapeutics ARCT|Multiplikator Forward P/S ETON (etonpharma.com)|Multiplikator Forward P/S Kamada Ltd KMDA|Fulcrum Therapeutics, Inc. - Multiplikator Forward P/S|ABEO - Multiplikator Forward P/S|MREO: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Protalix BioTherapeutics, Inc. (PLX)|PLRX (Pliant Therapeutics, Inc.) - Multiplikator Forward P/S|Applied Therapeutics Inc. - Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Rein Therapeutics Inc (RNTX)|Rasio rega marang pendapatan sing dikarepake GELS|Aytu BioPharma, Inc. - Multiplikator forward rega marang pendapatan|Chemomab Therapeutics (CMMB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SRx Health - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Polyrizon Limited PLRZ|AEZS: Multiplikator Forward P/S|CYTH: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan INZY|RPHM: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan CSCI (COSCIENS Biopharma)